Innovative
software and services provider Cresset, and Optibrium, a provider of
software solutions for drug discovery, today announce an agreement to
collaborate on the development of next-generation platforms. The innovative
companies will work together, combining unique approaches to help drug
discovery projects quickly identify novel, potent compounds with a high chance
of success downstream.
The
collaboration will involve a two-way exchange of technologies: Optibrium's ADME
[1] models, currently provided as a
plug-in module for its
StarDropTM software platform,
will be made available to users of Cresset's desktop applications. Similarly,
Cresset's
FieldAlignTM software, which
helps chemists understand the three-dimensional structure-activity-relationship
of their chemistry in order to design active compounds, will be made available
as an optional plug-in module for StarDrop, which helps project teams to
confidently target compounds with a good balance of properties for their
therapeutic objectives.
Achieving
a combination of potency with appropriate ADME and safety properties is
essential to the discovery of high quality drug candidates. Cresset's molecular
field
technology provides unique insight into the biological activity,
properties and interactions of molecules, which enables biologically meaningful
comparisons that are not limited by two-dimensional structure.
Optibrium's StarDrop platform helps to guide decisions on the design and
selection of compounds by integrating
in silico and experimentally
measured properties using a unique multi-parameter optimisation approach,
chemical space and Glowing Molecule
TM visualisations and predictive
modelling.
Dr.
Matthew Segall, CEO of Optibrium, said, "We are very happy to be working with
the team at Cresset. This collaboration furthers our aim to deliver leading
edge
in silico technologies directly to the desktop of all drug
discovery scientists through StarDrop's user friendly, interactive interface.
The new FieldAlign module in StarDrop will bring a powerful 3D view of compound
interactions that will complement StarDrop's existing 2D QSAR models."
Dr.
Robert Scoffin, CEO of Cresset, added "This collaboration is an excellent
opportunity for two companies to combine talents and technologies in order to
offer a better product to our combined customers. This highlights the power of
bringing together complementary technologies from leading-edge companies to
better address problems in Drug Discovery."
The technology shared under this
collaboration will form new components in upcoming releases of Optibrium's
StarDrop and Cresset's desktop applications. Full details of these exciting new
developments will be announced soon.
For more information about StarDrop and
Optibrium's software solutions please visit
www.optibrium.com,
alternatively please call +44 (0) 1223 815 900 or email
info@optibrium.com.
For more information about Cresset's
software and service solutions please visit
www.cresset-group.com, alternatively
please call +44 (0) 1707 356 120 or email
sales@cresset-group.com.
About Optibrium Ltd
Optibrium (
www.optibrium.com) is dedicated to providing software to guide decisions
involving complex, uncertain data in an intuitive way. Based in Cambridge, UK,
Optibrium has a global customer base ranging from top-ten pharmaceutical
companies to small biotechs and academic groups. Our mission is to continue to
develop new technologies that will optimise project strategy, reduce wasted
molecules and experiments, shorten timelines and improve the quality of
candidate compounds for our clients. Optibrium's primary product, StarDrop, is
focused on the drug discovery industry, helping guide scientists to make
decisions in the design and selection of high quality drug candidates. Visit
the online community at
http://www.optibrium.com/community/ for further discussions on improving the productivity of
drug discovery.
About Cresset Group Ltd
Cresset develops software for calculating and comparing the
molecular Field characteristics of chemical compounds. Field technology uses
the surface properties of molecules to evaluate their activities and
properties, rather than relying on 2D structure similarity, which enables
Cresset's users to find more interesting, novel and relevant results than other
methods. Cresset's Fields provide a smarter, structure independent way of
hit-finding, lead switching and lead optimization in drug discovery and other
chemistry-based research projects. Cresset's Field technologies have been
successfully applied to a very wide range of target classes, with and without
structural information, on over 100 projects for major pharmaceutical and
biotechnology companies.
www.cresset-group.com
[1] Absorption, Distribution, Metabolism
and Elimination